Table A1.

Efficacy of Ixabepilone Plus Capecitabine Combination: Progression-Free Survival in Measurable Disease Stratum—Overall Population and Prespecified Subgroups

Group	Ixabepilone Plus Capecitabine (n = 480)				Capecitabine (n = 480)				Hazard Ratio	95% CI
	No. of Events	No. of Subjects	PFS (months)		No. of Events	No. of Subjects	PFS (months)
			Median	95% CI			Median	95% CI
Overall population	446	480	6.2	5.59 to 6.77	457	480	4.4	4.14 to 5.42	0.79	0.69 to 0.90
Key subgroups
Triple negative	93	100	4.24	3.45 to 5.49	108	112	1.81	1.51 to 2.92	0.64	0.48 to 0.84
KPS 70%-80%	138	149	5.59	4.30 to 6.77	120	121	3.9	2.79 to 4.80	0.74	0.58 to 0.95
First line	91	98	5.55	4.24 to 6.77	80	81	3.1	1.81 to 4.07	0.64	0.47 to 0.87

Abbreviation: PFS, progression-free survival; KPS, Karnofsky performance status.